AlphAIAlphAI — Financial news for AI agents
quiverquant.comNOV 42 min read$CVS

CVS HEALTH ($CVS) Releases Q3 2026 Earnings

CVS Health reported Q3 2026 earnings of $2.09 per share, exceeding estimates by $0.42, with revenue of $108.4 billion, surpassing expectations by $2.66 billion. Insiders sold 3.37 million shares, while institutional investors showed mixed activity. Analysts' price targets range from $106 to $115.

Original reporting
quiverquant.com
Published Nov 4, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CVS HEALTH ($CVS) Releases Q3 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$CVSBullishHigh
01

Why it matters

The earnings beat could trigger buying interest, but recent insider sales and hedge fund outflows may create mixed signals.

02

Market read

Earnings beat provides a fresh catalyst for CVS stock, though recent insider and fund activity adds nuance.

03

What to watch

Insider sales and hedge fund reductions may temper upside momentum.

Relevance 8/10Novelty 9/10Timing: after-hours today

Background

CVS Health is a large U.S. pharmacy and health services retailer; earnings releases are closely watched.

Company-level read

Ticker impact

$CVSBullishHigh confidence
Context

CVS Health reported Q3 2026 earnings of $2.09 EPS and $108.4B revenue, both beating estimates.

Expected impact

likely upward move as market prices in the earnings beat

Evidence & confidence

EPS beat by $0.42 and revenue beat by $2.66B indicate stronger performance than expected.

Market effects

Sector

Healthcare sector may see modest lift as CVS outperforms expectations.

Regional

U.S. market sentiment could improve in the healthcare segment.

Global

Limited to U.S. investors; minimal global ripple.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short-term profit taking.

Key entities

  • Insider
    Larry Robbins

    Sold 3.37M shares over the past 6 months.

Read at source← All news

StoryCVS Health posts strong Q3 results and lifts full‑year EPS and cash‑flow outlook

Also covered by

6 outlets

Related articles

NOV 4
$CVSHigh

CVS Splits In Two, The Morning After The Midterms

CVS Health plans to split into two public companies by 2028. The insurance and benefits division will retain the CVS Health name, while the drugstores will become CVS Pharmacy. The move follows a 70% stock increase under CEO David Joyner, with Q3 sales rising to $108.4 billion. The split may preempt regulatory scrutiny of pharmacy benefit managers (PBMs).

finance.yahoo.com2 min
NOV 4
$CVSHighAI 8/10

CVS breezes past Q3 earnings estimates

CVS Health reported Q3 adjusted EPS of $2.09, surpassing estimates of $1.65. Revenue was $108.4B, exceeding forecasts. The company raised full-year EPS and cash flow guidance. Growth was driven by Health Services and Health Care Benefits segments, with operating income up 21.2%.

massmarketretailers.com2 min
NOV 4
$CVSHigh

CVS Health To Spinoff Its Retail Pharmacy Chain

CVS Health (CVS) plans to split into two publicly traded companies by mid-2028. The retail pharmacy chain, with 2025 sales of $37.66B, will become 'CVS Pharmacy,' while the insurance and benefits unit will retain 'CVS Health.' The company aims to cut $2B in costs. CVS stock has risen 17% in the past year, trading at $91.41.

tradingview.com2 min
NOV 4
$CVSMedAI 8/10

CVS Health Swings To Q3 Profit, Lifts FY26 Outlook; To Split Into Two; Shares Drop

CVS Health reported a Q3 profit, reversing last year's loss, and raised its FY26 outlook due to growth in key segments. The company plans to split into two publicly traded firms by 2028, focusing on healthcare solutions and retail pharmacy. Shares dropped 3.18% in pre-market trading. Q3 revenue rose 5.4% to $108.4B, with adjusted EPS at $2.09. FY26 net income is now expected to reach $9.002B, up from previous guidance.

rttnews.com2 min